

Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party — that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued

Issued: The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your patent



Section 1. Identifying Infor	mation				
Given Name (First Name) Michael A.	2. Surna Nauck	me (Last Name	e)		3. Date 12-October-2018
4. Are you the corresponding author?	Yes	✓ No	Correspon	ding Auth	nor's Name
5. Manuscript Title "Effect of liraglutide on cardiovascular	outcomes	in elderly pat	ients: post hoc	analysis	of a randomized controlled trial"
6. Manuscript Identifying Number (if you I M18-1569	know it)				
Section 2. The Work Under 0	Considera	tion for Pul	olication		
Did you or your institution at any time recany aspect of the submitted work (includir statistical analysis, etc.)? Are there any relevant conflicts of inte	g but not lir		, data monitorin		nent, commercial, private foundation, etc.) for study design, manuscript preparation,
Section 3. Relevant financia	lactivitie	s outside th	e submitted	work.	
	ribed in the	instructions.	Use one line for	or each e	icial relationships (regardless of amount entity; add as many lines as you need by the 36 months prior to publication .
Are there any relevant conflicts of inte	rest?	Yes No	o .		
If yes, please fill out the appropriate in	formation b	pelow.			
Name of Entity	Grant?	Personal N	Non-Financial	Other?	Comments
AstraZeneca		V			
Bayer Vital	V				
Berlin Chemie/ Menarini	1	1		1	Board Member/ Advisory Panel
Boehringer Ingelheim				V	Board Member/ Advisory Panel
Briyotol Myers Squibb		1			
Eli Lilly & Co.	✓	V		✓	Board Member/ Advisory Panel
Fractyl				V	Board Member/ Advisory Panel
GlaxoSmithKline	V	V		1	Board Member/ Advisory Panel



Name of Entity	Grant?	Personal Fees?	Non-Financial Support?	Other?	Comments
Hoffamn-La Roche	V	V		V	Board Member/ Advisory Panel
Merck Sharp & Dohm	V	V		V	Board Member/ Advisory Panel
Metacure		V			
Novartis	1			V	Board Member/ Advisory Panel
Novo Nordisk	1	1		1	Board Member/ Advisory Panel
Sanofi-Aventis		1			
Sunpharma		1			
St. Josef-Hospital		1			Employee
Takeda		1		V	Board Member/ Advisory Panel
Versatis		1			
Xoma		V			
Genentech		1		V	Advisory Panel
Medscape		V			
Section 4. Intellectual Propert Do you have any patents, whether plann Section 5. Relationships not of	ed, pend	ing or issue	CMD PROCESSION OF THE PARTY OF	nt to the	work? ☐ Yes ✔ No
Are there other relationships or activities potentially influencing, what you wrote i				influence	d, or that give the appearance of
Yes, the following relationships/cond					
At the time of manuscript acceptance, jo On occasion, journals may ask authors to	urnals wi disclose	ll ask autho further info	ors to confirm and ormation about re	d, if neces eported r	sary, update their disclosure statements. elationships.



Section 6.

Disclosure Statement

Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

MAN has received compensation for lectures or advisory board membership from AstraZeneca, Boehringer Ingelheim, Eli Lilly & co., Fractyl, GSK, Intarcia/ Servier, Menarini/ Berlin-Chemie, MSD and Novo Nordisk, Sun Pharma. He has received grant support from AstraZeneca, Boehringer Ingelheim, Eli Lilly & co., GSK, Menarini/ Berlin-Chemie, MSD and Novartis.

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

Prof. Dr. med. Michael A. Nauck

Leiter klinische Forschung Abteilung für Diabetologie

Universitätskynikyny/St. Josef-Hospital

Gudrunstr. 56, 44791 Bochum

Telefon: 0234 / 509-6332 o. 509-1 Telefax: 0234 / 509-2714

E-Mail: michael.nauck@rub.de



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued

Issued: The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your patent

Bain 1



Section 1. Identifying Inform	ation					
1. Given Name (First Name) Stephen	2. Surna Bain	me (Last Nam	e)		3. Date 12-October-2018	
4. Are you the corresponding author?	Yes	✓ No	Correspon	ding Autho	or's Name	
5. Manuscript Title Effect of liraglutide on cardiovascular o	utcomes ii	n elderly pat	ients: post hoc a	analysis o	f a randomized controlled trial	
6. Manuscript Identifying Number (if you kn M18-1569	ow it)					
Section 2. The Work Under Co	onsidera	tion for Pu	blication			
any aspect of the submitted work (including statistical analysis, etc.)? Are there any relevant conflicts of intere			s, data monitorin	g board, st	udy design, manuscript preparatio	٦,
Section 3. Relevant financial	activitie	s outside tl	he submitted	work.		
Place a check in the appropriate boxes i of compensation) with entities as descri clicking the "Add +" box. You should rep Are there any relevant conflicts of intere If yes, please fill out the appropriate info	bed in the port relations:	e instructions onships that Yes \(\bigcap \) N	s. Use one line f	or each er	ntity; add as many lines as you r	need by
Name of Entity	Grant?	Personal Fees?	Non-Financial Support?	Other?	Comments	
Sanofi	√				Clinical trial fees	
Novo Nordisk	✓				Clinical trial fees	
Sanofi		\checkmark			Speaker fees	
Novo Nordisk		\checkmark			Speaker fees	
Lilly/Bl		\checkmark			Speaker fees	
Astra Zeneka		\checkmark			Speaker fees	

Bain 2



Section 4. Intellectual Property Patents & Copyrights
Do you have any patents, whether planned, pending or issued, broadly relevant to the work? Yes Vo
Section 5. Relationships not covered above
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
Yes, the following relationships/conditions/circumstances are present (explain below):
✓ No other relationships/conditions/circumstances that present a potential conflict of interest
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.
Section 6. Disclosure Statement
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.
Dr. Bain reports grants from Sanofi, grants from Novo Nordisk, personal fees from Sanofi, personal fees from Novo Nordisk, personal fees from Lilly/BI, personal fees from Astra Zeneka, outside the submitted work; .

Evaluation and Feedback

 $Please\ visit\ \underline{http://www.icmje.org/cgi-bin/feedback}\ to\ provide\ feedback\ on\ your\ experience\ with\ completing\ this\ form.$

Bain 3



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued

Issued: The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your patent

Franek 1



Section 1.	Identifying Inform	ation					
1. Given Name (Fi Edward	rst Name)	2. Surnan Franek	ne (Last Nar	ne)		3. Date 12-October-2018	
4. Are you the cor	responding author?	Yes	✓ No	Correspond Matthew	_	or's Name	
5. Manuscript Title Effect of liragluti		utcomes in	elderly pa	tients: post hoc a	nalysis of	a randomized controlled trial	
6. Manuscript Ide	ntifying Number (if you kn	ow it)					
Section 2.	The Work Under Co	onsiderat	ion for P	ublication			
any aspect of the s statistical analysis, Are there any rel	ubmitted work (including	but not lim		its, data monitoring	-	ent, commercial, private foundation udy design, manuscript preparation	
Section 3.	Relevant financial	activities	outside '	the submitted	work.		
of compensation clicking the "Add Are there any rel	n) with entities as descri	bed in the port relationst?	instruction inships tha	ns. Use one line fo	or each en	ial relationships (regardless of a itity; add as many lines as you n e 36 months prior to publicati o	eed by
Name of Entity		Grant?	Personal Fees	Non-Financial Support?	Other?	Comments	
Astra Zeneca			√	√			
Bioton			✓				
Boehringer Ingelheir	n		\checkmark	✓			
Eli Lilly			\checkmark				
Mundipharma			√	✓			
Novo Nordisk			✓	✓			
Sanofi			✓				
Servier			✓	✓			

Franek 2



Section 4. Intellectual Property Patents & Copyrights
Do you have any patents, whether planned, pending or issued, broadly relevant to the work? Yes Vo
Section 5. Relationships not covered above
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
Yes, the following relationships/conditions/circumstances are present (explain below):
✓ No other relationships/conditions/circumstances that present a potential conflict of interest
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements On occasion, journals may ask authors to disclose further information about reported relationships.
Section 6. Disclosure Statement
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.
Dr. Franek reports personal fees and non-financial support from Astra Zeneca, personal fees from Bioton, personal fees and non-financial support from Boehringer Ingelheim, personal fees from Eli Lilly, personal fees and non-financial support from Mundipharma, personal fees and non-financial support from Novo Nordisk, personal fees from Sanofi, personal fees and non-financial support from Servier, outside the submitted work; .

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

Franek 3



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued

Issued: The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your patent

von Scholten 1



Section 1.	Identifying Inform	nation	
1. Given Name (Fii Bernt Johan	rst Name)	2. Surname (Last Name von Scholten	3. Date 12-October-2018
4. Are you the cor	responding author?	☐ Yes ✓ No	Corresponding Author's Name Matthew Gilbert
5. Manuscript Title Effect of liragluti		utcomes in elderly pation	ents: post hoc analysis of a randomized controlled trial
6. Manuscript Ider M18-1569	ntifying Number (if you kr	now it)	
Section 2.	The Work Under Co	onsideration for Pul	plication
any aspect of the s statistical analysis,	titution at any time rece ubmitted work (including	vive payment or services from the payment or services from the payments of the payment or services from the payment of the	om a third party (government, commercial, private foundation, etc.) for data monitoring board, study design, manuscript preparation,
Section 3.	Relevant financial	activities outside th	e submitted work.
of compensation) with entities as descri	ibed in the instructions.	whether you have financial relationships (regardless of amount Use one line for each entity; add as many lines as you need by were present during the 36 months prior to publication .
•	evant conflicts of intere out the appropriate info		
Name of Entity		Grant? Personal Fees?	Other? Comments
Novo Nordisk A/S			☐ Employer ☐
Continu A	l		
Section 4.	Intellectual Proper	rty Patents & Copy	rights
Do you have any	patents, whether plan	ned, pending or issued,	broadly relevant to the work? Yes Vo

von Scholten 2



Section 5. Polationships not severed above
Relationships not covered above
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
Yes, the following relationships/conditions/circumstances are present (explain below):
✓ No other relationships/conditions/circumstances that present a potential conflict of interest
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements On occasion, journals may ask authors to disclose further information about reported relationships.
Section 6. Disclosure Statement
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.
Dr. von Scholten reports other from Novo Nordisk A/S, from null, outside the submitted work; .

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

von Scholten 3



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued

Issued: The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your patent

Tornoee 1



Section 1. Identifying Inform	ation		
1. Given Name (First Name) Karen	2. Surname (Last Name) Tornoee		3. Date 12-October-2018
4. Are you the corresponding author?	Yes ✓ No	Corresponding Au	uthor's Name
5. Manuscript Title Effect of liraglutide on cardiovascular o	utcomes in elderly patien	ts: post hoc analysi	is of a randomized controlled trial
6. Manuscript Identifying Number (if you kr M18-1569	ow it)		
Section 2. The Work Under Co	onsideration for Publi	ication	
Did you or your institution at any time recei any aspect of the submitted work (including statistical analysis, etc.)? Are there any relevant conflicts of intere	but not limited to grants, d		nment, commercial, private foundation, etc.) for d, study design, manuscript preparation,
Section 3. Relevant financial	activities outside the	submitted work	
	bed in the instructions. Uport relationships that we est? Yes No	lse one line for eacl	ancial relationships (regardless of amount h entity; add as many lines as you need by the 36 months prior to publication.
Name of Entity	Grant? Personal No	on-Financial Support?	Comments
Novo Nordisk			Dr. Karen Tornoee is employed as Scientific Medical Director at Novo Nordisk A/S, Bagsvaerd, Denmark; Stockholder
Sortion A			
Section 4. Intellectual Proper	ty Patents & Copyri	ghts	
Do you have any patents, whether plans	ned, pending or issued, b	roadly relevant to t	the work? Yes No

Tornoee 2



Section 5. Relationships not sovered above
Relationships not covered above
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
Yes, the following relationships/conditions/circumstances are present (explain below):
✓ No other relationships/conditions/circumstances that present a potential conflict of interest
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements On occasion, journals may ask authors to disclose further information about reported relationships.
Section 6. Disclosure Statement
Disclosure Statement
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.
Dr. Tornoee reports personal fees and other from Novo Nordisk, outside the submitted work; .

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

Tornoee 3



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued

Issued: The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your patent

Rea 1



4. Are you the corresponding author? 5. Manuscript Title Semaglutide consistently reduces cardiovaserisk level: post hoc analyses of the SUSTAIN to 6. Manuscript Identifying Number (if you know it n/a Section 2. The Work Under Consideration of the Submitted work (including but a statistical analysis, etc.)? Are there any relevant conflicts of interest? If yes, please fill out the appropriate informate Excess rows can be removed by pressing the	ves Note Note Note Note Note Note Note Note	or Publication ices from a third grants, data mor No f you have mor	n d party (gover nitoring board	nment, commercial, private d, study design, manuscript	cardiovascular e foundation, etc.)
5. Manuscript Title Semaglutide consistently reduces cardiovase risk level: post hoc analyses of the SUSTAIN to 6. Manuscript Identifying Number (if you know it n/a Section 2. The Work Under Consideration of the Submitted work (including but it statistical analysis, etc.)? Are there any relevant conflicts of interest? If yes, please fill out the appropriate informatexcess rows can be removed by pressing the strazeneca pehringer Ingelheim it Lilly intofic.	deration for any year of the last of the l	n/a patients with ty me r Publication fices from a third grants, data mor No f you have mor	n d party (gover nitoring board) re than one 6	nment, commercial, private d, study design, manuscript	e foundation, etc.) preparation,
Section 2. The Work Under Consistently reduces cardiovass risk level: post hoc analyses of the SUSTAIN to 6. Manuscript Identifying Number (if you know it n/a Section 2. The Work Under Consistent Under Consist	deration for anyment or serving time to go time to below. If a "X" button. Person Fees	r Publication ices from a third grants, data mor No f you have mor	n d party (gover nitoring board re than one e	nment, commercial, private d, study design, manuscript entity press the "ADD" bu	e foundation, etc.) preparation,
The Work Under Consideration 2. The Work Under Consideration at any time receive part any aspect of the submitted work (including but it statistical analysis, etc.)? Are there any relevant conflicts of interest? If yes, please fill out the appropriate informatexcess rows can be removed by pressing the Name of Institution/Company Ovo Nordisk StraZeneca Dehringer Ingelheim Lilly Inofi	deration for serving the serving of limited to go the serving of t	ices from a third grants, data mor No f you have mor	d party (gover nitoring board re than one e	d, study design, manuscript entity press the "ADD" bu	preparation,
Did you or your institution at any time receive parany aspect of the submitted work (including but is statistical analysis, etc.)? Are there any relevant conflicts of interest? If yes, please fill out the appropriate informat Excess rows can be removed by pressing the Name of Institution/Company Grovo Nordisk traZeneca pehringer Ingelheim Lilly nofi	yment or servinot limited to go Yes tion below. If "X" button. Persor Fees	ices from a third grants, data mor No f you have mor	d party (gover nitoring board re than one e	d, study design, manuscript entity press the "ADD" bu	preparation,
Did you or your institution at any time receive parany aspect of the submitted work (including but is statistical analysis, etc.)? Are there any relevant conflicts of interest? If yes, please fill out the appropriate informat Excess rows can be removed by pressing the Name of Institution/Company Grovo Nordisk StraZeneca Dehringer Ingelheim Lilly Inofi	yment or servinot limited to go Yes tion below. If "X" button. Persor Fees	ices from a third grants, data mor No f you have mor	d party (gover nitoring board re than one e	d, study design, manuscript entity press the "ADD" bu	preparation,
any aspect of the submitted work (including but is statistical analysis, etc.)? Are there any relevant conflicts of interest? If yes, please fill out the appropriate informatexcess rows can be removed by pressing the Name of Institution/Company Ovo Nordisk StraZeneca Dehringer Ingelheim Lilly Inofi	Yes [tion below. If e"X" button. Persor	No f you have mor	nitoring board	d, study design, manuscript entity press the "ADD" bu	preparation,
ovo Nordisk ItraZeneca Dehringer Ingelheim Lilly nofi	Fees	Suppo		.	·
traZeneca [pehringer Ingelheim [Lilly [nofi [Suppo	rt?		
ehringer Ingelheim [Lilly nofi	✓			Advisory panel, Speake	er's bureau
Lilly [✓			Advisory panel, Speake	er's bureau
nofi [✓			Advisory panel, Speake	er's bureau
	✓			Advisory panel, Speake	er's bureau
keda	✓			Advisory panel, Speake	er's bureau
	√			Speaker's bureau	
Section 3. Polovent financial activ	•••				
Relevant financial activ	vities outsic	de the subm	litted work	•	
Place a check in the appropriate boxes in the of compensation) with entities as described clicking the "Add +" box. You should report in Are there any relevant conflicts of interest?					

Rea 2



Section 4. Intellectual Property Patents & Copyrights
Do you have any patents, whether planned, pending or issued, broadly relevant to the work? Yes Vo
Section 5. Relationships not covered above
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
Yes, the following relationships/conditions/circumstances are present (explain below):
No other relationships/conditions/circumstances that present a potential conflict of interest
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements On occasion, journals may ask authors to disclose further information about reported relationships.
Section 6. Disclosure Statement
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.
Dr. Rea reports personal fees from Novo Nordisk, personal fees from AstraZeneca, personal fees from Boehringer Ingelheim, personal fees from Eli Lilly, personal fees from Sanofi, personal fees from Takeda, during the conduct of the study; .

Evaluation and Feedback

 $Please\ visit\ \underline{http://www.icmje.org/cgi-bin/feedback}\ to\ provide\ feedback\ on\ your\ experience\ with\ completing\ this\ form.$

Rea 3



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued

Issued: The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your patent



If yes, please fill out the appropriate information below.

ICMJE Form for Disclosure of Potential Conflicts of Interest

Section 1. Identifying Ir	nformation						
1. Given Name (First Name) John	2. Surname (Last Name) Buse	3. Date 11-October-2018					
4. Are you the corresponding author	? Yes 🗸 No	Corresponding Author's Name					
5. Manuscript Title Effect of liraglutide on cardiovasc	ular outcomes in elderly patient	s: post hoc analysis o	of a randomized controlled trial				
6. Manuscript Identifying Number (if M18-1569	you know it)	_					
Section 2. The Work Und	der Consideration for Public	ation					
Did you or your institution at any time receive payment or services from a third party (government, commercial, private foundation, etc.) for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)? Are there any relevant conflicts of interest? Yes No If yes, please fill out the appropriate information below. If you have more than one entity press the "ADD" button to add a row. Excess rows can be removed by pressing the "X" button.							
Name of Institution/Company	Grant•	n-Financial Other?	Comments				
Novo Nordisk		V	Conducted as part of my full-time employment at UNC. Fees for consultation paid to UNC; Travels/meals/lodging for contracted activities.				
Section 3. Relevant fina	ncial activities outside the s	ubmitted work.					
Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were present during the 36 months prior to publication . Are there any relevant conflicts of interest? Ves No							



Name of Entity	Grant?	Personal Fees	Non-Financial Support?	Other?	Comments
Eli Lilly	√		√	√	Conducted as part of my full-time employment at UNC. Fees for consultation paid to UNC; Travels/meals/lodging for contracted activities.
GI Dynamics	√		✓	✓	Conducted as part of my full-time employment at UNC. Fees for consultation paid to UNC; Travels/meals/lodging for contracted activities.
Elcylex Therapeutics, Inc.			√	✓	Conducted as part of my full-time employment at UNC. Fees for consultation paid to UNC; Travels/meals/lodging for contracted activities.
Merck	✓		/	✓	Conducted as part of my full-time employment at UNC. Fees for consultation paid to UNC; Travels/meals/lodging for contracted activities.
Metavention			V	✓	Conducted as part of my full-time employment at UNC. Fees for consultation paid to UNC; Travels/meals/lodging for contracted activities.
vTv Therapeutics			V	✓	Conducted as part of my full-time employment at UNC. Fees for consultation paid to UNC; Travels/meals/lodging for contracted activities.
PhaseBio Pharmaceuticals, Inc				✓	Stock options; Fees for consultation paid to UNC.
AstraZeneca	✓		V	✓	Conducted as part of my full-time employment at UNC. Fees for consultation paid to UNC; Travels/meals/lodging for contracted activities.
Dance Biopharm			V	✓	Conducted as part of my full-time employment at UNC. Fees for consultation paid to UNC; Travels/meals/lodging for contracted activities.
Medtronic Minimed	✓				



Name of Entity	Grant?	Personal Fees?	Non-Financial Support?	Other?	Comments
Sanofi	✓		V	✓	Conducted as part of my full-time employment at UNC. Fees for consultation paid to UNC; Travels/meals/lodging for contracted activities.
Johnson & Johnson	✓				
Boehringer-Ingelheim	✓				
GlaxoSmithKline	✓				
Intarcia Therapeutics	✓			√	Conducted as part of my full-time employment at UNC. Fees for consultation paid to UNC.
Lexicon	✓		/	✓	Conducted as part of my full-time employment at UNC. Fees for consultation paid to UNC; Travels/meals/lodging for contracted activities.
Scion NeuroStim	✓				
Orexigen	√		V	√	Conducted as part of my full-time employment at UNC. Fees for consultation paid to UNC; Travels/meals/lodging for contracted activities.
Takeda	√		V	√	Conducted as part of my full-time employment at UNC. Fees for consultation paid to UNC; Travels/meals/lodging for contracted activities.
Adocia			/	✓	Conducted as part of my full-time employment at UNC. Fees for consultation paid to UNC; Travels/meals/lodging for contracted activities.
Theracos	✓				
Novo Nordisk	✓		/	✓	Conducted as part of my full-time employment at UNC. Fees for consultation paid to UNC; Travels/meals/lodging for contracted activities.
Mellitus Health (formerly Insulin Algorithms)				√	Stock options
Bayer	\checkmark				
Dexcom				√	Conducted as part of my full-time employment at UNC. Fees for consultation paid to UNC.



Fractyl				✓	Conducted as part of my full-time employment at UNC. Fees for consultation paid to UNC.	
Shenzen HighTide				✓	Conducted as part of my full-time employment at UNC. Fees for consultation paid to UNC.	
NovaTarg				✓	Conducted as part of my full-time employment at UNC. Fees for consultation paid to UNC.	
AstraZeneca HealthCare Foundation				✓	I was a member of this non-profit board. No payments.	
Neurimmune AG		\checkmark				
Senseonics				✓	Conducted as part of my full-time employment at UNC. Fees for consultation paid to UNC; Travels/meals/lodging for contracted activities.	
Stability Health				✓	Stock Options	
Do you have any patents, whether place Section 5. Relationships no	anned, pendi	ng or issue		nt to the	e work? ☐ Yes 🗸 No	
Are there other relationships or activi			nerceive to have i	nfluence	ad or that give the appearance of	
potentially influencing, what you wro				imaciice	ea, or that give the appearance of	
Yes, the following relationships/conditions/circumstances are present (explain below):						
✓ No other relationships/conditions	/circumstand	es that pro	esent a potential o	conflict o	of interest	
At the time of manuscript acceptance On occasion, journals may ask author					ssary, update their disclosure stateme relationships.	



Section 6.

Disclosure Statement

Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

Dr. Buse reports grants, non-financial support and other from Novo Nordisk, during the conduct of the study; grants, non-financial support and other from Eli Lilly, grants, non-financial support and other from Gl Dynamics, non-financial support and other from Elcylex Therapeutics, Inc., grants, non-financial support and other from Merck, non-financial support and other from Metavention, non-financial support and other from vTv Therapeutics, other from PhaseBio Pharmaceuticals, Inc, grants, non-financial support and other from AstraZeneca, non-financial support and other from Dance Biopharm, grants from Medtronic Minimed, grants, non-financial support and other from Johnson & Johnson, grants from Boehringer-Ingelheim, grants from GlaxoSmithKline, grants and other from Intarcia Therapeutics, grants, non-financial support and other from Crexigen, grants, non-financial support and other from Orexigen, grants, non-financial support and other from Takeda, non-financial support and other from Adocia, grants from Theracos, grants, non-financial support and other from Novo Nordisk, other from Mellitus Health (formerly Insulin Algorithms), grants from Bayer, other from Dexcom, other from Fractyl, other from Shenzen HighTide, other from NovaTarg, other from AstraZeneca HealthCare Foundation, personal fees from Neurimmune AG, other from Senseonics, other from Stability Health, outside the submitted work;

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued **Issued:** The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether

earning royalties or not **Royalties:** Funds are coming in to you or your institution due to your

patent

Gilbert 1



Section 1. Identifying Infor	rmation								
1. Given Name (First Name) Matthew	2. Surname (Last Name) Gilbert	3. Date 11-October-2018							
Are you the corresponding author? ✓ Yes No									
5. Manuscript Title Effect of liraglutide on cardiovascular outcomes in elderly patients: post hoc analysis of a randomized controlled trial									
6. Manuscript Identifying Number (if you	know it)								
Section 2. The Work Under	Consideration for Publication								
		arty (government, commercial, private foundation, etc.) for oring board, study design, manuscript preparation,							
Are there any relevant conflicts of inte	erest?								
Section 3. Polovent financia									
Relevant financia	al activities outside the submitt	ed work.							
of compensation) with entities as des clicking the "Add +" box. You should i	cribed in the instructions. Use one lin report relationships that were preser	u have financial relationships (regardless of amount ne for each entity; add as many lines as you need by nt during the 36 months prior to publication.							
Are there any relevant conflicts of inte									
If yes, please fill out the appropriate in	normation below.								
Name of Entity	Grant? Personal Non-Financ	Other? Comments							
Novo Nordisk		Consulting Fees							
Sanofi		Consulting Fees							
Section 4. Intellectual Prop	erty Patents & Copyrights								
Do you have any patents, whether planned, pending or issued, broadly relevant to the work? Yes Vo									

Gilbert 2



Section 5. Relationships not covered above
helationships not covered above
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
Yes, the following relationships/conditions/circumstances are present (explain below):
No other relationships/conditions/circumstances that present a potential conflict of interest
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements On occasion, journals may ask authors to disclose further information about reported relationships.
Section 6. Disclosure Statement
Disclosure Statement
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.
Dr. Gilbert reports personal fees from Novo Nordisk, personal fees from Sanofi, outside the submitted work; .

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

Gilbert 3



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued

Issued: The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your patent



Section 1. Identifying Inform	io		
Identifying Inform	nation		
1. Given Name (First Name) Esteban	2. Surname (Last Name) Jodar Gimeno		3. Date 21-October-2018
4. Are you the corresponding author?	☐ Yes ✓ No	Corresponding Author Matthew P Gilbert	r's Name
5. Manuscript Title "Effect of liraglutide on cardiovascular o	outcomes in elderly patien	ts: post hoc analysis of	f a randomized controlled trial"
6. Manuscript Identifying Number (if you kr M18-1569	now it)	_	
Section 2. The Work Under Co	onsideration for Public	cation	
Did you or your institution at any time rece any aspect of the submitted work (including statistical analysis, etc.)?			
Are there any relevant conflicts of interest	est? 🗸 Yes 🗌 No		
If yes, please fill out the appropriate info Excess rows can be removed by pressin		e more than one entit	y press the "ADD" button to add a row.
Name of Institution/Company	Grant	n-Financial other?	Comments
Novo Nodkisk	✓		
			,
Cartiana			
Section 3. Relevant financial	activities outside the s	ubmitted work.	
Place a check in the appropriate boxes of compensation) with entities as descr clicking the "Add +" box. You should repart there any relevant conflicts of interest.	ibed in the instructions. Us port relationships that wer	se one line for each en	tity; add as many lines as you need by
If yes, please fill out the appropriate info			
Name of Entity	Grant•	n-Financial other?	Comments
Novo Nordisk	✓		
MSD	✓		
illy	V		



Name of Entity	Grant?	Personal Fees?	Non-Financial Support?	Other?	Comments	
Janssen	√	✓				
Pfizer	✓	\checkmark				
Astra Zeneca	✓	\checkmark				
Sanofi	√	✓				
Section 4. Intellectual Propert	y Pate	ents & Co _l	pyrights			
Do you have any patents, whether plann	ed, pend	ing or issue	ed, broadly releva	nt to the	work? Yes 🗸 No	
Section 5. Relationships not c	overed	above				
Are there other relationships or activities potentially influencing, what you wrote i				influence	d, or that give the appearance of	
Yes, the following relationships/cond	litions/cir	cumstance	es are present (exp	olain belo	w):	
No other relationships/conditions/cir	cumstan	ces that pre	esent a potential	conflict of	finterest	
At the time of manuscript acceptance, jo On occasion, journals may ask authors to					· ·	nents.
Section 6. Disclosure Stateme	nt					
Based on the above disclosures, this form below.	n will aut	omatically (generate a disclos	sure state	ment, which will appear in the box	
Dr. Jodar Gimeno reports grants and per personal fees from Novo Nordisk, MSD, L				-		



Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued

Issued: The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your patent



Section 1. Identifying Inform	ation							
Given Name (First Name) Richard	2. Surname (Last N Pratley	ame)		3. Date 16-October-2018				
4. Are you the corresponding author?	☐ Yes 🗸 No	•	Corresponding Author's Name Matthew GILBERT					
5. Manuscript Title Effect of liraglutide on cardiovascular outcomes in elderly patients: post hoc analysis of a randomized controlled trial.								
6. Manuscript Identifying Number (if you kn	ow it)							
Section 2. The Work Under Co	onsideration for	Publication						
Did you or your institution at any time receive payment or services from a third party (government, commercial, private foundation, etc.) for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)? Are there any relevant conflicts of interest? Yes No								
If yes, please fill out the appropriate info Excess rows can be removed by pressing	rmation below. If y	ou have more thar	n one entity	press the "ADD" button to add a	row.			
Name of Institution/Company	Grant? Persona	Non-Financial Support?	Other?	Comments				
Novo Nordisk			✓ fo	lovo Nordisk has provided funding or writing support, having ponsored the original trial				
Novo Nordisk	✓			Grant paid to institution (Florida Hospital, a nonprofit organization)				
					1			
Section 3. Relevant financial a	activities outsid	e the submitted	work.					
Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount								
of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were present during the 36 months prior to publication .								
Are there any relevant conflicts of intere	st? 🗸 Yes	No						
If yes, please fill out the appropriate info	rmation below.							



Name of Entity	Grant?	Personal Fees	Non-Financial Support?	Other?	Comments
AstraZeneca				✓	Fees for lecturing and consultancy paid to institution (Dr. Richard Pratley's services were paid for directly to Florida Hospital, a nonprofit organization.)
Boehringer-Ingelheim				✓	Fees for consultancy paid to institution (Dr. Richard Pratley's services were paid for directly to Florida Hospital, a nonprofit organization.)
Gilead Scienses	✓				Grant paid to institution (Florida Hospital, a nonprofit organization)
GlaxoSmithKline				✓	Fees for consultancy paid to institution (Dr. Richard Pratley's services were paid for directly to Florida Hospital, a nonprofit organization.)
Hanmi Pharmaceutical Co., Ltd.				✓	Fees for consultancy paid to institution (Dr. Richard Pratley's services were paid for directly to Florida Hospital, a nonprofit organization.)
Janssen Scientific Affairs, LLC				√	Fees for consultancy paid to institution (Dr. Richard Pratley's services were paid for directly to Florida Hospital, a nonprofit organization.)
Lexicon Pharmaceuticals	✓				Grant paid to institution (Florida Hospital, a nonprofit organization)
Ligand Pharmaceuticals, Inc.	✓			✓	Grant and fees for consultancy paid to institution (Dr. Richard Pratley's services were paid for directly to Florida Hospital, a nonprofit organization.)
Lilly	✓			✓	Grant and fees for consultancy paid to institution (Dr. Richard Pratley's services were paid for directly to Florida Hospital, a nonprofit organization.)
Merck	✓			√	Grant and fees for consultancy paid to institution (Dr. Richard Pratley's services were paid for directly to Florida Hospital, a nonprofit organization.)



Name of Entity	Grant?	Personal Fees	Non-Financial Support?	Other?	Comments			
Novo Nordisk	✓			√	Grant and fees for lecturing and consultancy paid to institution (Dr. Richard Pratley's services were paid for directly to Florida Hospital, a nonprofit organization.)			
Pfizer				✓	Fees for consultancy paid to institution (Dr. Richard Pratley's services were paid for directly to Florida Hospital, a nonprofit organization.)			
Sanofi-Aventis US, LLC	✓				Grant paid to institution (Florida Hospital, a nonprofit organization)			
Takeda	✓			✓	Grant and fees for lecturing and consultancy paid to institution (Dr. Richard Pratley's services were paid for directly to Florida Hospital, a nonprofit organization.)			
Eisai, Inc.				✓	Fees for consultancy paid to institution (Dr. Richard Pratley's services were paid for directly to Florida Hospital, a nonprofit organization.)			
Sanofi US Services, Inc.				√	Consultancy			
Section 4. Intellectual Property Patents & Copyrights Do you have any patents, whether planned, pending or issued, broadly relevant to the work? Yes No Section 5. Relationships not assured above.								
Relationships not c								
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?								
Yes, the following relationships/conditions/circumstances are present (explain below): No other relationships/conditions/circumstances that present a potential conflict of interest								
	At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.							



Section 6.

Disclosure Statement

Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

Dr. Pratley reports other from Novo Nordisk, grants from Novo Nordisk, during the conduct of the study; other from AstraZeneca, other from Boehringer-Ingelheim, grants from Gilead Scienses, other from GlaxoSmithKline, other from Hanmi Pharmaceutical Co., Ltd., other from Janssen Scientific Affairs, LLC, grants from Lexicon Pharmaceuticals, grants and other from Ligand Pharmaceuticals, Inc., grants and other from Lilly, grants and other from Merck, grants and other from Novo Nordisk, other from Pfizer, grants from Sanofi-Aventis US, LLC, grants and other from Takeda, other from Eisai, Inc., other from Sanofi US Services, Inc., outside the submitted work. Except for other from Sanofi US Services, Inc., Dr. Richard Pratley's services were paid for directly to Florida Hospital, a nonprofit organization.

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued

Issued: The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your patent



	ı								
Section 1.	Identifying Informa	ation							
1. Given Name (Fi José Francisco K		2. Surnar Saraiva	ne (Last Nar	ne)	3. Date 09-April-2018				
4. Are you the cor	responding author?	Yes	✓ No	-	Corresponding Author's Name Matthew GILBERT				
5. Manuscript Title Effect of liraglutide on cardiovascular outcomes in elderly patients: post hoc analysis of a randomized controlled trial									
6. Manuscript Ider	ntifying Number (if you kno	ow it)							
Section 2.	The Work Under Co	nsidera	tion for P	ublication					
	ubmitted work (including					ent, commercial, private foundation, etc.) for udy design, manuscript preparation,			
•	evant conflicts of interes			No 					
	out the appropriate info be removed by pressing			u have more than	one enti	ty press the "ADD" button to add a row.			
Name of Institut	ion/Company	Grant?	Personal Fees?	Non-Financial Support?	Other?	Comments			
Novo Nordisk					✓	Novo Nordisk has provided funding for writing support, having sponsored the original trial			
Section 3.	Relevant financial a	ctivities	outside	the submitted	work.				
Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were present during the 36 months prior to publication . Are there any relevant conflicts of interest?									
If yes, please fill o	out the appropriate info	rmation b	elow.						
Name of Entity		Grant?	Personal Fees?	Non-Financial Support?	Other?	Comments			
Amgen		✓	✓			Consulting fees and travel support; grant support			
lanssen		✓	✓			Consulting fees and travel support; grant support			



Name of Entity	Grant?	Personal Fees	Non-Financial Support?	Other?	Comments		
Novo Nordisk	√	✓			Consulting fees and travel support; grant support; attendance at advisory boards		
Eli Lilly & Co	✓	✓			Consulting fees and travel support; grant support		
AstraZeneca	✓	✓			Consulting fees and travel support; grant support; attendance at advisory boards		
Novartis	✓	✓			Consulting fees and travel support; grant support; attendance at advisory boards		
Sanofi Aventis		✓			Consulting fees and travel support		
Boehringer Ingelheim	✓	✓			Consulting fees and travel support; grant support; attendance at advisory boards		
Section 4. Intellectual Property Patents & Copyrights Do you have any patents, whether planned, pending or issued, broadly relevant to the work? Yes Vo							
Section 5. Relationships not covered above							
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?							
Yes, the following relationships/conditions/circumstances are present (explain below): No other relationships/conditions/circumstances that present a potential conflict of interest							
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.							

Section 6.

Disclosure Statement

Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

Dr. Saraiva reports other from Novo Nordisk, during the conduct of the study; grants and personal fees from Amgen, grants and personal fees from Janssen, grants and personal fees from Novo Nordisk, grants and personal fees from Eli Lilly & Co, grants and personal fees from AstraZeneca, grants and personal fees from Novartis, personal fees from Sanofi Aventis, grants and personal fees from Boehringer Ingelheim, outside the submitted work;

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued **Issued:** The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether

earning royalties or not **Royalties:** Funds are coming in to you or your institution due to your

patent



Section 1. Identifying Infor	mation				
1. Given Name (First Name) Søren	2. Surname (Last Name Rasmussen)	3. Date 20-November-2018		
4. Are you the corresponding author?	Yes ✓ No	Corresponding Auth Matthew GILBERT	Corresponding Author's Name Matthew GILBERT		
5. Manuscript Title Effect of liraglutide on cardiovascular	outcomes in elderly pation	ents: post hoc analysis c	of a randomized controlled trial		
6. Manuscript Identifying Number (if you	know it)				
Section 2. The Work Under	Consideration for Pul	olication			
any aspect of the submitted work (including statistical analysis, etc.)? Are there any relevant conflicts of interesting the state of the submitted work (including statistics).	ng but not limited to grants erest? Yes Notes If you l	, data monitoring board, s	nent, commercial, private foundation, etc.) for tudy design, manuscript preparation, tity press the "ADD" button to add a row.		
Name of Institution/Company		Non-Financial Support? Other	Comments		
Novo Nordisk			Novo Nordisk has provided funding for writing support, having sponsored the original trial		
Section 3. Relevant financia	nl activities outside th	e submitted work.			
	cribed in the instructions.	. Use one line for each e	cial relationships (regardless of amount entity; add as many lines as you need by the 36 months prior to publication .		
Are there any relevant conflicts of inte)			
If yes, please fill out the appropriate in	formation below.				
Name of Entity	Grant? Personal Fees?	Non-Financial Other	Comments		
Novo Nordisk			Full-time employee and share-holder		





Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.